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In this editorial we review the data on the use of multi-dose ROM (Rifampicin, Ofloxacin
and Minocycline) as an alternative treatment to WHO-MDT (World Health Organisation
multidrug therapy) comprising rifampicin, clofazimine and dapsone. There is now sufficient
evidence to warrant a large trial of this new regimen. The adverse effects of the current MDT
regimen are probably under-estimated and this new regimen would reduce these adverse
effects. Ofloxacin and minocycline have been shown to be more bactericidal than dapsone
and clofazimine in both mice and clinical trials.1–3 The single monthly dosing might improve
compliance which is also a major challenge.
In 1997 a randomised double-blind trial comparing single dose rifampicin, ofloxacin and
minocycline was published4 and rapidly approved by the 7th Expert Committee on Leprosy5
in 1998 as treatment for single lesion leprosy. There were methodological problems in the
study underpinning this recommendation, and at the time one of us voiced reservations about
the new regimen.6 However, the regimen has now been used much more widely with studies
being done in India and Brazil and there is now substantial experience in using it. A recent
systematic review7 has assessed all the studies comparing ROM and MDT and found
14 studies that could be included in the review. Four of these compared single dose ROM
with WHO-MDT for treating pauci-bacillary leprosy and combining these studies it was
found that single dose ROM is slightly less effective than WHO-MDT with a relative risk of
0·91 (95% confidence intervals 231%) but still has a very high cure rate.
Only two studies have been reported using multiple doses of ROM in lepromatous leprosy
(LL). One in the Philippines by Villahermosa et al.,8 comparing 21 patients with borderline
lepromatous and LL who were given either monthly ROM (n ¼ 10) or the standard MDT
(n ¼ 11) which comprised monthly rifampicin (600mg), and clofazimine (300mg) with daily
dapsone (100mg) and clofazimine (50mg) for 24 months. These patients had a mean
Bacterial Index (BI) of 4 (range 2·7–5·1) at entry to the study and it fell to 1·18 (range 0–3·5).
Correspondence to: Diana N.J. Lockwood, London School of Hygiene & Tropical medicine, Keppel St, London
WC1E 7HT. (e-mail: diana.lockwood@lshtm.ac.uk)
Lepr Rev (2012) 83, 241–244
0305-7518/12/064053+04 $1.00 q Lepra 241
The patients assigned to WHOMB-MDT had similar falls in their BI’s. Patients’ skin lesions
improved (measured by a score) as did the histological appearance on their skin biopsies
during treatment. A study done in Brazil9 had a similar design, allocating patients to either
monthly ROM or MB-MDT. These patients mostly had LL and both groups had a similar
fall in BI (3·5 to 2·5) after 24 months of treatment and similar clinical and histological
improvements. In the Philippines study the BI continued to fall after the completion of
antibiotic treatment and no relapses were recorded during the subsequent 64 months after
treatment. No toxicities were recorded in patients receiving ROM, whereas all patients on
WHO-MDT developed clofazimine-induced pigmentation. These are important and
encouraging studies which should be repeated on a larger scale with a randomised design.
It is encouraging to see that the BI fell during this intermittent monthly treatment. It is
probably critical in leprosy chemotherapy to give sufficient antibiotic treatment over a long
enough duration. The slow metabolism ofM. leprae probably requires several hits over a long
duration to achieve a sufficient kill. Evidence from other studies showing that ultra- short
course duration of multi drug treatment does not produce a lasting bacterial cure, a study done
in the Comoros Islands giving 6 weeks of quadruple drug treatment had a relapse rate of
15%.10 There have also been high relapse rates after the WHO sponsored 4-week course of
MDT. In both studies patients were then given 24 months of WHO-MDT treatment.8
The three drugs that comprise MDT all have recognised adverse effects. Dapsone has the
largest range with skin and haematological adverse effects predominating. There has been
little systematic reporting of adverse effects. The early studies on MDT focussed on bacterial
cure and relapse rates with no reporting of adverse effects.11 Clinicians are well aware of the
problems. Goulart12 has reported that 37·9% of patients in Minas Gerais, Brazil taking MDT
had adverse effects. A retrospective study13 from Vitoria, Espiritu Sanctu, Brazil using good
case definitions found that 45% of patients had adverse effects attributable to MDT with
43·85 having effects attributable to dapsone, 12·3% to Rifampicin and 9·25 to clofazimine.
Two patients developed severe leucopenia and one died. A subsequent study from that centre
(Deps Lep Rev submitted) found that 24·7% of patients developed haemolytic anaemia after
starting MDT, and this was probably an underestimate because not all patients were tested for
anaemia. In most centres routine monitoring for adverse effects is not done and so these may
be missed. Dapsone hypersensitivity syndrome has also been reported from Nepal14 where it
occurs in 2% patients taking MDT and causes death in 0·25%; it is also increasing in
frequency in India.15
The skin pigmentation caused by clofazimine is troublesome. It accumulates in leprosy
lesions and so often highlights lesions on the face and it causes a generalised tanning of the
skin and an icthyosis on the legs. There is little good data on the frequency of this adverse
effect. However patients and their communities are well aware of this adverse effect and
associate it with treatment for leprosy. Clinicians including ourselves (DNJL, MG) switch
patients off the clofazimine component of MDT to reduce these visible adverse effects. The
U-MDT trial report commented that patients did not find clofazimine pigmentation
troublesome but the authors do not report whether systematic data on skin pigmentation was
collected.16
Compliance is ‘the elephant in the room’ with our current multidrug regimens. We have
very little good routine data on compliance. One study from India17 showed that in Assam in
2002–2005 35·1% of patients starting on MDT were defaulting whilst in Delhi rates of 60%
for defaulting have been reported.18 In the Philippines a 30% default rate has been reported.19
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Attending a clinic does not ensure compliance and Weiand et al. found in India that 33% of
patients attending for multidrug therapy did not have urine metabolites in their urine.20
These different factors indicate the need for new approaches and easier regimens for
treating leprosy. The monthly ROM schedule has the advantage of being simpler and has
fewer side-effects. We propose that a large ROM trial be done comparing 12 months of
monthly single dose ROM against 12 months of WHO MB-MDT in multibacillary patents.
Patients with a BI over 4 could be randomised to receive either 24 months of ROM or
24 months of WHO-MDT. The trials should incorporate good data collection on clinical
improvement, adverse effects, default rates, reactions and neuritis and patient satisfaction.
The main outcome measure would be relapse rates and patients would need to be followed for
10 years to pick up late relapses. The research challenge of identifying surrogate markers for
relapse could also be addressed in this trial. It is likely that adverse effects would be fewer
when a single monthly does is given but monitoring would be important. Minocycline when
used in a daily dose caused pigmentation21 so careful checking would need to be done to
ensure that this was not happening with a monthly dose. Adequate follow-up involving both
active and then passive would be important to detect late relapses. The safety of using of
multiple dose ROM in children would need to be supported by a literature review and
pharmacokinetic data of minocycline. Ofloxacin is in use as a second line agent for treating
typhoid fever in children.22 Giving ROM would be more expensive than using WHO MDT
but a single monthly dose would not be prohibitively expensive. There are potential
operational advantages since it might be easier to implement monthly supervision with this
regimen and so improve detection of reactions and nerve damage. As the drugs have fewer
side effects patients will be more likely to comply with the medication even if they do not
attend clinic. Innovative approaches such as aiding compliance by the use of SMS messages
could be tried. The use of ROM could also help reduce the stigma associated with leprosy; the
patients in the Philippines trial commented that they were able to keep their treatment private.
The possibilities of using other agents such as rifapentine instead of rifampicin and
moxifloxacin instead of ofloaxacin should also be considered. Both agents have been shown
to be bactericidal against M. leprae in mouse models.23–24 Moxifloxacin has been shown to
be significantly bactericidal in small studies in patients with lepromatous leprosy,25–26 and so
could be considered as an alternative drug for inclusion in a monthly regimen.
Developing studies using ROM is a potentially exciting way of improving leprosy
treatment for patients and helping in the next stage of leprosy control.
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